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Abstract We evaluated clinical and diagnostic indicators of
severe C. difficile infection (CDI) and their association with
poor clinical outcome. A total of 210 patients positive accord-
ing to PCR (toxin B: tcdB) were included, with patients
having a median age of 62 years and a Charlson co-
morbidity index (CI) score of 5. Ninety-one percent (n=191)
were positive by toxigenic culture and 61% (n=129) had stool
toxin. Toxin-positive patients had significantly higher fecal
lactoferrin (mean 316 μg/g versus 106 μg/g stool; p<0.0001).
Forty percent of patients (n=85) were infected with ribotype
027 and significantly more of these patients had measurable
stool toxin (79 % vs. 50 %; p<0.0001). The mean fecal
lactoferrin was significantly higher for toxin-positive 027
CDI compared with the 027 toxin-negative group (317 vs
60 μg/g; p=0.0014). Ribotype 027 CDI with stool toxin
showed a higher all-cause, 100-day mortality compared with
non-027 with stool toxin (36 % vs 18 %; p=0.017). Logistic
regression univariate analysis for odds ratio (OR) and pvalues
revealed that age (OR=1.1), intensive care unit treatment
(OR=2.7), CI (OR=1.2), 027 CDI (OR=2.1), white blood
cell count (OR=1.0), albumin level (OR=0.1), and stool
toxin-positive 027 CDI (OR=2.5) were significantly associ-
ated with 100-day mortality (p<0.05). In conclusion, CDI
PCR-positive patients with 027 infection and stool toxin have
increased lactoferrin and are at an increased risk of death.
Introduction
C. difficile infection (CDI) is a common complication for
hospitalized patients. Identifying and appropriately treating
patients who are more likely to suffer poor outcomes from
this infection would improve clinical outcome and decrease
healthcare costs. In the United States, the mortality rate from
CDI has increased from 5.7 deaths per million people in 1999
to 23.7 deaths per million in 2004 [1]. The emergence of
ribotype 027 BI/NAP1 in the early 2000s has led to outbreaks
of CDI with more severe disease and an increased death rate in
hospitalized patients [2–9]. The increased severity and trans-
mission seen with the ribotype 027 has correlated with a
combination of elevated early in vitro toxin production,
increased sporulation, efficient germination, and resis-
tance to fluoroquinolones [10–15]. Even though this strain
has continued to increase in prevalence, the association
with more severe disease is not consistent among studies,
raising questions as to what cofactors contribute to severe
CDI and worse outcomes [16–20]. Further studies are
needed to target more accurately the combination of variables
that contribute to severe infections and poor outcomes
following CDI.
Laboratory diagnosis of CDI has changed over recent years
resulting in molecular testing for the toxin genes (tcdA and
tcdB) becoming more common in the United States, while the
detection of toxin continues to be the test of choice in Europe
[21, 22]. Bothmethods offer advantages. Molecular assays are
highly sensitive showing between a true-positive rate of 75
and 85 % for toxigenic culture in many comparative studies
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[21]. GDH detection and toxin enzyme-linked immunoassay
(EIA) tests, on the other hand, indicate the presence of the
actively growing vegetative toxigenicC. difficile and correlate
with worse outcome [23, 24]. These different tests have
generated an increasing need for defined clinical criteria
and host biomarkers that accurately identify patients who
require aggressive treatment.
Various clinical criteria and blood biomarkers have been
associated with increased CDI severity and poor clinical
outcome. These factors include age, medical co-morbidities,
clinical symptoms of fever and abdominal pain, increased
peripheral white blood cell count (WBC), elevated serum
creatinine, and low serum albumin [25– 32].C. difficile toxins
act locally to create intense intestinal inflammation that can be
seen by colonoscopy or radiographic imaging, or measured in
stool by fecal leucocytes or elevated fecal lactoferrin [19,
33–36]. More recently, fecal lactoferrin and fecal IL-8, both
biomarkers of inflammation, have been shown to identify
more severe cases of CDI [37–40]. In our study, we evaluated
a novel combination of patient characteristics, clinical labora-
tory results, and fecal parameters with the infecting ribotype to
evaluate their relationship with poor clinical outcome, as
measured by 100-day, all-cause mortality for hospitalized
patients positive for C. difficile according to PCR.
Materials and methods
Study subjects
Sequential in-patients from May 2010 to August 2011 with a
clinical diagnosis of CDI and positive for tcdB according to
PCR (BD GeneOhm C diff Assay, Becton Dickinson,
Franklin Lakes, NJ, USA, or Xpert C. difficile, Cepheid,
Sunnyvale, CA, USA) were identified according to the
protocol (HSR-IRB #13630, NIH/NIAID 5K23A1074681).
Patients were deemed eligible if hospitalized at the time of
CDI diagnosis, ≥ 18 years old, no recent history of chronic
diarrhea (≥ 4 weeks), and adequate volume of stool for
subsequent testing. Enrolled subjects were followed for
clinical outcome by review of medical records and telephone
contact following diagnosis.
Chart reviews
Reviews of medical records were carried out by participating
clinical research team members to record patient demo-
graphics, medical co-morbidities, and clinically obtained
blood and serum laboratory results (peripheral white blood
cell count, serum albumin, and serum creatinine) at the time of
CDI diagnosis. During hospitalization, all-cause treatment in
the intensive care unit (ICU) and 100-day, all-cause mortality
were recorded. An age-unadjusted Charlson co-morbidity
Index score for assessing co-morbid disease was calculated
for each patient, as described previously [41, 42].
Toxin detection
C. difficile testing was done at the hospital clinical microbiol-
ogy laboratory using tcdB PCR (BD GeneOhm C diff Assay,
Becton Dickinson, or XpertC. difficile, Cepheid) according to
the manufacturer’s instructions. A fecal specimen from eligi-
ble tcdB-positive subjects on the day of CDI diagnosis was
frozen at −80 °C and shipped to TechLab, Blacksburg, VA,
USA, for biomarker testing and toxigenic culture, as well as
PCR ribotyping. Stool toxin B was detected by tissue culture
Bacterial culture and ribotyping
Toxigenic culture was obtained using the ethanol shock meth-
od previously described by Boone et al. [43] and C. difficile
isolates were evaluated for PCR ribotype using the procedure
developed by Stubbs et al. [44].
Statistical analysis
A summary was tabulated to describe patient demographic
and diagnostic characteristics. In cases where a skew was
above 1.5 in magnitude (i.e. greater than 1.5 or less than -
1.5), medians and ranges were reported. Otherwise, means
and standard deviations (sd) were provided. Significance test-
ing for percentage differences was based on Fisher’s Exact
Test and Wilcoxon rank sum test for continuous variables.
Logistic regression was used to assess the bivariate relation-
ships between 100-day all-cause mortality and the available
clinical and lab results. A predictive model was formed in the
logistic regression framework using the Bayesian Information
Criteria (BIC) to determine a parsimonious subset of variables
which were highly predictive of 100-day all-cause mortality.
Predictive accuracy was assessed using the concordance in-
dex, or c-statistic, which measures the tradeoff between true
positive and false positive rates across the range of model
predictions. The c-statistic is defined between zero and one. A
c-statistic of 0.5 corresponds to a diagnostic rule as effective as
a coin flip, and higher c-statistics are better. A significant
difference was defined as having a p-value of≤0.05.
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using the C. DIFFICILE TOX-B Test (TechLab® Inc., Blacks-
burg, VA) including a neutral goat serum control as described
by Boone et al. [37]
Fecal lactoferrin analysis
The amount of fecal lactoferrin (μg/g stool) was quantitatively
determined using the IBD-SCAN® test, according to the
package insert (TechLab®).
Results
A total of 210 adult hospitalized patients who tested positive
for C. difficile according to PCR (for tcdB) were enrolled. The
cohort was 50 % (n=105) female, mean age was 60.4
(sd=16.8) years and 44 % (n=93) were≥65 years old.
The mean Charlson co-morbidity index score was 5 (sd=3)
points and the most frequently reported co-morbid conditions
included 46 % (n=96) having moderate to severe renal failure
and 34 % (n=72) suffering with dementia. A 63%majority of
subjects (n=132) had a score of>3 points using the Charlson
co-morbidity index. Ninety-five subjects (45 %) were treated
in the intensive care unit (ICU) during this hospitalization and
50 subjects (24 %) died within 100 days of CDI diagnosis,
with a mean of 36 (sd=29) days until death. The recorded
cause of death for the 50 subjects included 15 (30 %) un-
known, 14 (28 %) sepsis with 2 documented as CDI sepsis, 6
(12 %) malignancy, 5 (10 %) respiratory failure, 4 (8 %) liver
disease, 4 (8%) congestive heart failure, and 2 (4%) infection.
The patient demographics and clinical characteristics are listed
in Table 1.
Based on stool studies for CDI, 91 % of subjects (n=191)
were positive by toxigenic culture, and stool toxin, as deter-
mined by tissue culture, was detected in 61 % (n=129). The
top 5 most prevalent toxigenic ribotypes in this patient cohort
were ribotype 027 at 40 % (n=85), ribotype 014 at
10 % (n=20), ribotype 106 at 6 % (n=12), ribotype 056 at
6 % (n=12), and ribotype 053 at 5 % (n=9).
Systemic and intestinal inflammatory biomarkers and
indicators of C. difficile disease were measured in blood
and fecal specimens to assess disease severity and the
overall medical condition of the patient (Table 2).
Thirty-two percent of subjects (n=67) had WBC>15×
109/L. Serum albumin was measured in 77 % of enrolled
subjects (n=162) and 20 % of these subjects (n=33) had
low serum albumin levels (≤ 2.5 g/dL). Creatinine levels
were≥1.5 mg/dL for 28 % (n=59) of subjects. A majority
of the cohort (77 %; n=161) had elevated lactoferrin
(≥7.25 μg/g stool) and nearly half (37 %; n=78) had
lactoferrin levels over 100 μg/g stool. The frequency of
each diagnostic parameter for the study cohort is listed in
Table 1 Patient characteristics.Mean and standard deviation are reported
for continuous variables. The skew for all continuous variables was below
1.5 in magnitude. Sample sizes ranged from 206 to 210 for these
measures
Patient characteristics Frequency Percent
Age in years, mean=60.4, sd=16.8
<65 117 55.7
≥65 93 44.3
Male gender 105 50






Myocardial infarction 54 25.7
Congestive heart failure 51 24.3
Peripheral vascular disease 24 11.4
Cerebrovascular disease 31 14.8
Dementia/delirium 72 34.3
Connective tissue disorder 16 7.6
Chronic pulmonary dysfunction 49 23.3
Gastric ulcer disease 32 15.2
Mild liver disease 17 8.1
Diabetes (no end organ damage) 37 17.6
Hemiplegia 16 7.7
Moderate-severe renal disease 96 46.2
Diabetes with end organ damage 28 13.4
Any tumor 60 28.6
Leukemia 5 2.4
Lymphoma 7 3.4
Moderate to severe liver disease 28 13.5
Metastatic solid tumor 20 9.7
AIDS 3 1.4
Intensive care unit 95 45.2
100-day mortality 50 23.8
Table 2 Diagnostic parameters. Frequencies and percentages are report-
ed for categorical variables. Sample sizes range between 207 and 210
except for albumin, which has a sample size of n=162
Diagnostic parameters Frequency (%)
PCR + 210 (100)
Tissue culture + 129 (61.4)
Toxigenic culture + 191 (91.0)
Ribotype 027 CDI 85 (40.5)





<7.25, μg/g 49 (23.3)
7.25–100 μg/g 83 (39.5)
>100 μg/g 78 (37.1)
Albumin level
<2.5 g/dL 33 (20.4)
≥2.5 g/dL 129 (79.6)
Creatinine
<1.5 mg/dL 148 (71.5)
≥1.5 mg/dL 59 (28.5)
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Table 2 and the reported means or medians depending on
the skew are listed in Table 3.
Each subject, all of whom were PCR+for tcdB, was placed
in a group based on positive (+) or negative (−) toxigenic
culture (tox culture) and stool toxin (tissue culture; TC). The
diagnostic categories were: group 1 tox culture (+) tissue
culture (+)(61 %; n=129), group 2 tox culture (+) tissue
culture (−) (30 %; n=62), and group 3 tox culture (−) tissue
culture (−) (9 %; n=19). Using this grouping, median fecal
lactoferrin was significantly higher for group 1 subjects
(90 μg/g stool) compared with groups 2 (24 μg/g stool) and
3 (20 μg/g stool; Wilcoxon rank sum p<0.0001 and p=0.006
respectively; Fig. 1).WBCmedian counts differed significant-
ly between group 1 (12.2×109/L) and 3 (7.6×109/L; p=0.003;
Fig. 2). There were no differences observed among the three
groups for serum albumin and serum creatinine.
A series of univariate logistic regression analyses were
performed to assess the association with all-cause mortality
within 100 days of CDI diagnosis. Table 4 shows odds ratios,
confidence intervals, and p values for the association between
predictive variables and 100-day mortality. Age (p<0.0001),
Charlson co-morbidity index (p=0.0002), ICU treatment
(p=0.0027), 027 infection (p=0.0271), WBC count
(p=0.0283), albumin (p=0.0199) ,and the combination
of 027 infection with stool toxin (p=0.0059) showed signifi-
cant associations with increased mortality. The variables in
Table 4 were then used as candidate predictors of 100-
day, all-cause mortality in a logistic regression model
excluding albumin levels, which has substantially fewer
observations than the other variables. A model selection
was performed by enumerating all possible models
formed from the ten candidate predictors, and the model
with the lowest value of Bayesian Information Criteria
(BIC) was chosen. This model selection revealed that
age (0<0.001), ICU treatment (p=0.003), Charlson co-
morbidity index (p<0.001) formed a model with the best
trade-off between overall predictive ability of death and
complexity as measured by BIC. The true-positive trade-off of
this model was good, as measured by a C-statistic =0.774, and
supports these clinical characteristics as being significant in a
high-risk patient population. When considering biomarkers
for CDI, among the subjects who were stool toxin-positive,
the subjects with 027 CDI had a significantly higher mortality
rate (36 %; n=24) than that (18 %; n=11) for subjects with
non027 infections (p=0.017). The remaining groups, 027- and
non-027-infected subjects with no measurable stool toxin had
mortality rates of 17 % (n=18) vs 19 % (n=62) respectively.
Discussion
In our study cohort, hospitalized patients with PCR-positive
C. difficile infection having measurable stool toxin had signif-
icantly higher fecal lactoferrin and peripheral WBC, as indi-
cators of more inflammation and severe CDI. Univariate
analysis showed that age, Charlson co-morbidity index, ICU
treatment, increased peripheral WBC, elevated lactoferrin,
Table 3 Diagnostic parameters. Skew, median, minimum, and
maximum are reported for continuous variables with skew above a magni-
tude of 1.5. Mean and standard deviation are reported for continuous
variables with skew less than or equal to 1.5 in magnitude
Diagnostic parameters Summary statistics
White blood cell count, skew, median
(minimum, maximum)
1.7, 11.4 (0.2, 53.9)
Lactoferrin, skew, median (minimum,
maximum)
3.3, 48.5 (0, 2,823)
Albumin level, mean (sd) 3.0 (0.65)
Creatinine, skew, median (minimum,
maximum)
3.0, 0.9 (0.4, 9.9)
Fig. 1 Comparison of lactoferrin
median levels between diagnostic
groups. Medians are noted with a
bold line and bars and dots show
lower and upper quartiles. Units
for lactoferrin are shown in
parenthesis. p values not included
in the plot are above 0.05
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decreased albumin, and elevated creatinine were significantly
associated with death within 100 days of CDI diagnosis.
Multiple studies have shown the link between stool toxin/
inflammation and severe CDI/mortality [23, 24, 37–39, 40,
45, 46]. In a study by Baker et al. [46], patients with CDI who
were positive for stool toxin according to EIA had a mortality
rate of 38 % compared with 11 % for patients who were PCR-
positive/EIA-negative. They also showed that patients with
stool toxin were also more likely to suffer with prolonged
diarrhea (2; p<0.001). In another study by Bloomfield et al.
[26], blood parameters including WBC, serum albumin,
creatinine, and C-reactive protein were assessed as risk
factors for 30-day all-cause mortality in patients who
were positive for stool toxin [26]. Based on a multivariate
model, WBC >15×109/L and serum albumin levels <2.5 g/dL
were significantly associated with mortality. The patient co-
hort included in the study by Bloomfield et al. [26] was similar
to our cohort and included hospitalized patients with a median
age of 74 years, with 78 % having a Charlson co-morbidity
index score >3. Patients in our study were also older, with
44 % of patients being over 65 years and 71 % having a
Charlson co-morbidity index score of >3. Our results support
the clinical association of having stool toxin with risk of death
in older CDI patients and further show that these patients
suffer more intestinal inflammation, as indicated by higher
lactoferrin levels. In addition, we determined that patients
infected with ribotype 027 in combination with stool toxin
and higher lactoferrin had a significantly higher mortality rate
than toxin-negative 027-infected patients and all non-027
groups. Our logistic regression model using age, ICU treat-
ment, and Charlson co-morbidity index was also successful at
predicting death for this high-risk cohort (C-statistic=0.774).
These findings contribute to the growing evidence that sup-
ports the clinical utility for both PCR and stool toxin detection
in identifying patients with C. difficile disease for appropriate
treatment. We also show results that confirm the significance
for identifying the infecting ribotype in a high-risk population
and raise an important question on whether this information
would modify treatment and improve patient outcome.
Further studies are needed to determine the effects of toxin
levels produced by ribotypes like ribotype 027 and the poten-
tial link between circulating toxin and mortality as described
Fig. 2 Comparison of white
blood cell (WBC) median counts
in the diagnostic groups. Medians
are noted with a bold line and,
bars and dots show lower and
upper quartiles. Units for WBC
count are shown in parenthesis
p values not included in the plot
are above 0.05
Table 4 Univariate analysis for
a combination of patient
characteristics and fecal and
blood biomarkers for an
association with increased
mortality. p values≥0.05 are
considered significant
Effect Odds ratio est Lower CL Upper CL Prob Chi Sq n
Age 1.051 1.025 1.077 <0.0001 210
Sex 0.729 0.385 1.381 0.3319 210
Charlson index 1.235 1.105 1.38 0.0002 210
ICU 2.737 1.416 5.29 0.0027 210
027 CDI 2.064 1.086 3.926 0.0271 210
WBC 1.038 1.004 1.073 0.0283 209
Lactoferrin 1.000 1.000 1.001 0.1407 210
Albumin 0.503 0.282 0.897 0.0199 162
Creatinine 1.019 0.828 1.254 0.8577 207
027 and stool toxin + 2.512 1.304 4.839 0.0059 210
All stool toxin + 1.638 0.828 3.239 0.1561 210
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recently in an animal model study by Kuehne et al. [47]. In
this recent study, stain R20291, which produces toxins A and
B along with binary toxin (CDT), was mutated to have com-
binations of toxins A and B, and CDTexpression to assess the
role of CDT in causing disease. Interestingly, the mutant strain
only expressing CDT killed 3 out of 9 infected hamsters.
Disease presentation in these animals was atypical and only
included wet tail and evidence of small bowel inflammation.
The authors went on to conclude that these results suggest the
role of increased virulence for C. difficile strains like ribotype
027 with binary toxin [47]. In another study by Koon et al.
[48], human colonic biopsies and isolated human monocytes
were used to show induced expression of the inflammatory
cytokines TNFα and IL-β by toxins A and B. In addition,
infusions with monoclonal antibodies against toxin A and B
were used to reduce the cytokine levels and protect epithelial
cells from damage in human colonic tissue [48]. Our findings,
along with these recent studies, further confirm the role of
C. difficile toxin in causing intestinal inflammation and tissue
damage, leading to a higher risk of death. In our patient cohort,
027-infected patients may have higher amounts of stool toxin,
possibly causing systemic disease and death. Further studies
are needed to determine the effects of toxin levels produced by
ribotypes like ribotype 027 and the potential link between
circulating toxin and mortality.
Our study confirms the clinical relevance of detecting stool
toxin in patients who are PCR-positive for C. difficile. Patients
with stool toxin, elevated lactoferrin, and infected with
ribotype 027 are at an increased risk of death. A combination
of clinical criteria, blood and fecal biomarkers for disease
severity, and identifying the infecting ribotype should be
considered in the evaluation of older, sicker patients with
suspected CDI.
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